SOPHIA: Second Interim OS Analysis of Margetuximab + CT vs Trastuzumab + CT for HER2+ MBC After Previous HER2 Therapy

December 10-14, 2019; San Antonio, Texas
In patients with HER2+ metatstatic breast cancer after prior anti-HER2 therapy, margetuximab + chemotherapy continues to provide PFS benefit vs trastuzumab + chemotherapy with similar OS benefit in the second interim survival analysis of SOPHIA.
Format: Microsoft PowerPoint (.ppt)
File Size: 204 KB
Released: December 20, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Daiichi Sankyo, Inc.
Genentech
Merck Sharp & Dohme Corp
Puma Biotechnology
Seattle Genetics

Related Content

Joyce O’Shaughnessy, MD, provides insights on key studies in HR-positive/HER2-negative breast cancer from 2019 SABCS for Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Released: January 31, 2020

Sara Tolaney, MD, MPH, provides insights on key studies on the treatment of HER2-negative and triple-negative breast cancer from 2019 SABCS for Clinical Care Options (CCO)

Sara Tolaney, MD, MPH Released: January 27, 2020

CME-certified Webcast of a CCO symposium at SABCS 2019 featuring expert perspectives on evolving strategies for treating HR-positive, HER2-negative advanced breast cancer

Joyce O'Shaughnessy, MD
Program Director
Hope S. Rugo, MD Eric P. Winer, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits US Physicians: maximum of 1.75 Medical Knowledge MOC point(s) Released: January 21, 2020 Expiration: January 20, 2021

CCO faculty Dr. Heather McArthur provides insights on trastuzumab deruxtecan and tucatinib for patients with HER2+ MBC who have progressed on standard-of-care HER2-targeted therapies

Heather McArthur, MD, MPH Released: January 21, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?